In Case You Haven’t Noticed: The Hartford Financial Services Group, Inc. (HIG), Progenics Pharmaceuticals, Inc. (PGNX)

A look at its monthly performance shows that The Hartford Financial Services Group, Inc. (NYSE:HIG) has recorded a 0.1% gain over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -10.13% and is now up by 9.81% since start of this year. The equity price rose 1.6% this week, a trend that has led to both investors and traders taking note of the stock. Its equity price climbed by 18.07% over the past three months which led to its overall six-month decrease to stand at -0.95%.

The shares of The Hartford Financial Services Group, Inc. (HIG) dropped by -11.51% or -$6.35 from its last recorded high of $55.16 which it attained on April 27 to close at $48.81 per share. Over the past 52 weeks, the shares of The Hartford Financial Services Group, Inc. has been trading as low as $40.54 before witnessing a massive surge by 20.4% or $8.27. This price movement has led to the HIG stock receiving more attention and has become one to watch out for. It jumped by 0.43% on Thursday and this got the market excited. The stock’s beta now stands at 0.72 and when compared to its 200-day moving average and its 50-day moving average, HIG price stands 0.73% above and 3.69% above respectively. Its average daily volatility for this week is 0.91% which is less than the 1.16% recorded over the past month.

Experts from research firms are bullish about the near-term performance of The Hartford Financial Services Group, Inc. with most of them predicting a $56.67 price target on a short-term (12 months) basis. The average price target by the analysts will see a 16.1% rise in the stock and would lead to HIG’s market cap to surge to $20.34B. The stock has been rated an average 2.4, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 22 analysts that track The Hartford Financial Services Group, Inc. (NYSE:HIG) and find out that 11 of them rated it as a Hold. 11 of the 11 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

A look at HIG technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 60.21 point. Its trading volume has lost -1203906 shares compared to readings over the past three months as it recently exchanged 1356094 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 2560000 shares, and this is 0.53 times the normal volume.

The price of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) currently stands at $4.42 after it went up by $0.21 or 4.99% and has found a strong support at $4.17 a share. If the PGNX price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $3.91 mark would also be bad for the stock as it means that the stock would plunge by 11.54% from its current position. However, if the stock price is able to trade above the resistance point around $4.58, then it could likely surge higher to try and break the upward resistance which stands at $4.73 a share. Its average daily volatility over the past one month stands at 4.95%. The stock has plunged by 7.92% from its 52-weeks high of $4.07 which it reached on Jun. 08, 2018. In general, it is 18.1% above its 52-weeks lowest point which stands at $3.62 and this setback was observed on Dec. 24, 2018.

Analysts have predicted a price target for Progenics Pharmaceuticals, Inc. (PGNX) for 1 year and it stands at an average $10.9/share. This means that it would likely increase by 146.61% from its current position. The current price of the stock has been moving between $4.07 and $4.48. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $6.5. On the other hand, one analyst is super bullish about the price, setting a target as high as $14.

The PGNX stock Stochastic Oscillator (%D) is at 37.78%, which means that it is currently neutral. The shares P/S ratio stands at 23.21 which compares to the 49.52 recorded by the industry or the 8.39 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 5.3% over the past five years.

Analysts view Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) as a Buy, with 1.6 consensus rating. Reuters surveyed 5 analysts that follow PGNX and found that 0 of those analysts rated the stock as a Hold. The remaining 5 were divided, with 5 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Progenics Pharmaceuticals, Inc. (PGNX) shares or sell it if they already own it.